• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰腺腺癌诊断中的成像模态:敏感性、特异性及诊断准确性的系统评价与荟萃分析

Imaging modalities in the diagnosis of pancreatic adenocarcinoma: A systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy.

作者信息

Toft James, Hadden William J, Laurence Jerome M, Lam Vincent, Yuen Lawrence, Janssen Anna, Pleass Henry

机构信息

Nepean Clinical School, University of Sydney, Australia.

Northern Clinical School, University of Sydney, Australia.

出版信息

Eur J Radiol. 2017 Jul;92:17-23. doi: 10.1016/j.ejrad.2017.04.009. Epub 2017 Apr 24.

DOI:10.1016/j.ejrad.2017.04.009
PMID:28624015
Abstract

BACKGROUND

Pancreatic cancer, primarily pancreatic ductal adenocarcinoma (PDAC), accounts for 2.4% of cancer diagnoses and 5.8% of cancer death annually. Early diagnoses can improve 5-year survival in PDAC. The aim of this systematic review was to determine the sensitivity, specificity and diagnostic accuracy values for MRI, CT, PET&PET/CT, EUS and transabdominal ultrasound (TAUS) in the diagnosis of PDAC.

METHODS

A systematic review was undertaken to identify studies reporting sensitivity, specificity and/or diagnostic accuracy for the diagnosis of PDAC with MRI, CT, PET, EUS or TAUS. Proportional meta-analysis was performed for each modality.

RESULTS

A total of 5399 patients, 3567 with PDAC, from 52 studies were included. The sensitivity, specificity and diagnostic accuracy were 93% (95% CI=88-96), 89% (95% CI=82-94) and 90% (95% CI=86-94) for MRI; 90% (95% CI=87-93), 87% (95% CI=79-93) and 89% (95% CI=85-93) for CT; 89% (95% CI=85-93), 70% (95% CI=54-84) and 84% (95% CI=79-89) for PET; 91% (95% CI=87-94), 86% (95% CI=81-91) and 89% (95% CI=87-92) for EUS; and 88% (95% CI=86-90), 94% (95% CI=87-98) and 91% (95% C=87-93) for TAUS.

CONCLUSION

This review concludes all modalities, except for PET, are equivalent within 95% confidence intervals for the diagnosis of PDAC.

摘要

背景

胰腺癌,主要是胰腺导管腺癌(PDAC),每年占癌症诊断病例的2.4%,癌症死亡病例的5.8%。早期诊断可提高PDAC患者的5年生存率。本系统评价的目的是确定MRI、CT、PET&PET/CT、EUS和经腹超声(TAUS)在诊断PDAC时的灵敏度、特异度和诊断准确性值。

方法

进行一项系统评价,以识别报告MRI、CT、PET、EUS或TAUS诊断PDAC的灵敏度、特异度和/或诊断准确性的研究。对每种检查方法进行了成比例Meta分析。

结果

共纳入来自52项研究的5399例患者,其中3567例为PDAC患者。MRI的灵敏度、特异度和诊断准确性分别为93%(95%CI=88-96)、89%(95%CI=82-94)和90%(95%CI=86-94);CT分别为90%(95%CI=87-93)、87%(95%CI=79-93)和89%(95%CI=85-93);PET分别为89%(95%CI=85-93)、70%(95%CI=54-84)和84%(95%CI=79-89);EUS分别为91%(95%CI=87-94)、86%(95%CI=81-91)和89%(95%CI=87-92);TAUS分别为88%(95%CI=86-90)、94%(95%CI=87-98)和91%(95%CI=87-93)。

结论

本评价得出结论,除PET外,所有检查方法在诊断PDAC时在95%置信区间内等效。

相似文献

1
Imaging modalities in the diagnosis of pancreatic adenocarcinoma: A systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy.胰腺腺癌诊断中的成像模态:敏感性、特异性及诊断准确性的系统评价与荟萃分析
Eur J Radiol. 2017 Jul;92:17-23. doi: 10.1016/j.ejrad.2017.04.009. Epub 2017 Apr 24.
2
The diagnostic performance of CT versus FDG PET-CT for the detection of recurrent pancreatic cancer: a systematic review and meta-analysis.CT 与 FDG PET-CT 诊断复发胰腺癌的效能比较:系统评价和荟萃分析。
Eur J Radiol. 2018 Sep;106:128-136. doi: 10.1016/j.ejrad.2018.07.010. Epub 2018 Jul 12.
3
MRI vs. CT for pancreatic adenocarcinoma vascular invasion: comparative diagnostic test accuracy systematic review and meta-analysis.MRI 与 CT 对胰腺腺癌血管侵犯的诊断价值比较:系统评价和 Meta 分析。
Eur Radiol. 2023 Oct;33(10):6883-6891. doi: 10.1007/s00330-023-09659-0. Epub 2023 Apr 21.
4
The Role of 18F-FDG PET/CT and PET/MRI in Pancreatic Ductal Adenocarcinoma.18F-FDG PET/CT 和 PET/MRI 在胰腺导管腺癌中的作用。
Abdom Radiol (NY). 2018 Feb;43(2):415-434. doi: 10.1007/s00261-017-1374-2.
5
Value of EUS in early detection of pancreatic ductal adenocarcinomas in patients with intraductal papillary mucinous neoplasms.EUS 在早期检测伴有胰管内乳头状黏液性肿瘤的胰腺导管腺癌中的价值。
Endoscopy. 2014 Jan;46(1):22-9. doi: 10.1055/s-0033-1353603. Epub 2013 Nov 11.
6
Prospective comparison of (4S)-4-(3-F-fluoropropyl)-L-glutamate versus F-fluorodeoxyglucose PET/CT for detecting metastases from pancreatic ductal adenocarcinoma: a proof-of-concept study.前瞻性比较 (4S)-4-(3-F-氟丙基)-L-谷氨酸与 F-氟脱氧葡萄糖 PET/CT 检测胰腺导管腺癌转移:一项概念验证研究。
Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):810-820. doi: 10.1007/s00259-018-4251-5. Epub 2019 Jan 11.
7
[Value of endoscopic ultrasound-guided fine needle aspiration in pretest prediction and diagnosis of pancreatic ductal adenocarcinoma].[内镜超声引导下细针穿刺在胰腺导管腺癌术前预测及诊断中的价值]
Nan Fang Yi Ke Da Xue Xue Bao. 2018 Sep 30;38(10):1171-1178. doi: 10.3969/j.issn.1673-4254.2018.10.04.
8
Multimodality imaging of pancreatic ductal adenocarcinoma: a review of the literature.胰腺导管腺癌的多模态影像学:文献综述。
HPB (Oxford). 2012 Oct;14(10):658-68. doi: 10.1111/j.1477-2574.2012.00508.x. Epub 2012 Jun 14.
9
Meta-analysis of CT and MRI for differentiation of autoimmune pancreatitis from pancreatic adenocarcinoma.CT 和 MRI 对自身免疫性胰腺炎与胰腺腺癌鉴别诊断的荟萃分析。
Eur Radiol. 2021 May;31(5):3427-3438. doi: 10.1007/s00330-020-07416-1. Epub 2020 Nov 4.
10
A review study on early detection of pancreatic ductal adenocarcinoma using artificial intelligence assisted diagnostic methods.人工智能辅助诊断方法在胰腺导管腺癌早期检测中的应用研究综述。
Eur J Radiol. 2023 Sep;166:110972. doi: 10.1016/j.ejrad.2023.110972. Epub 2023 Jul 11.

引用本文的文献

1
Early Detection of Pancreatic Cancer: Current Advances and Future Opportunities.胰腺癌的早期检测:当前进展与未来机遇
Biomedicines. 2025 Jul 15;13(7):1733. doi: 10.3390/biomedicines13071733.
2
Diagnostic performance of artificial intelligence based on contrast-enhanced computed tomography in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis.基于对比增强计算机断层扫描的人工智能在胰腺导管腺癌中的诊断性能:一项系统评价和荟萃分析。
Abdom Radiol (NY). 2025 Jul 2. doi: 10.1007/s00261-025-05089-2.
3
A Systematic Review of Cost-Effectiveness Studies on Pancreatic Cancer Screening.
胰腺癌筛查成本效益研究的系统评价
Curr Oncol. 2025 Apr 11;32(4):225. doi: 10.3390/curroncol32040225.
4
Current Approaches of Pancreatic Cancer Surveillance in High-Risk Individuals.高危个体胰腺癌监测的当前方法
J Gastrointest Cancer. 2025 Feb 11;56(1):61. doi: 10.1007/s12029-025-01184-1.
5
Advances in Endoscopic Ultrasonography-Based Diagnosis of Pancreatic Lesions: Narrative Review.基于内镜超声的胰腺病变诊断进展:叙述性综述
Cancers (Basel). 2025 Jan 7;17(2):172. doi: 10.3390/cancers17020172.
6
A noninvasive urinary microRNA-based assay for the detection of pancreatic cancer from early to late stages: a case control study.一种基于无创尿液微小RNA的检测胰腺癌早晚期的检测方法:一项病例对照研究。
EClinicalMedicine. 2024 Nov 12;78:102936. doi: 10.1016/j.eclinm.2024.102936. eCollection 2024 Dec.
7
Role of molecular imaging in prognosis, diagnosis, and treatment of gastrointestinal cancers: An update on new therapeutic methods.分子成像在胃肠道癌症预后、诊断及治疗中的作用:新治疗方法的最新进展
World J Methodol. 2024 Dec 20;14(4):93461. doi: 10.5662/wjm.v14.i4.93461.
8
Biomarker Discovery for Early Detection of Pancreatic Ductal Adenocarcinoma (PDAC) Using Multiplex Proteomics Technology.使用多重蛋白质组学技术发现用于早期检测胰腺导管腺癌(PDAC)的生物标志物
J Proteome Res. 2025 Jan 3;24(1):315-322. doi: 10.1021/acs.jproteome.4c00752. Epub 2024 Dec 19.
9
An update on pancreatic cancer imaging, staging, and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment.胰腺癌成像、分期以及PACT-UK放射学模板在新辅助治疗前后的应用进展
Br J Radiol. 2025 Jan 1;98(1165):13-26. doi: 10.1093/bjr/tqae217.
10
Predictors of occult metastases in potentially Resectable pancreatic ductal adenocarcinoma.潜在可切除胰腺导管腺癌隐匿性转移的预测因素
Surg Open Sci. 2024 Jul 22;20:222-229. doi: 10.1016/j.sopen.2024.07.010. eCollection 2024 Aug.